AIRS Airsculpt Technologies, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1870940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.3%
TTM net income YoY47.7%
TTM EPS YoY60.0%
Revenue 3-yr CAGR-7.9%
Net income 3-yr CAGR—
Margins
Gross margin60.2%
Operating margin-4.7%
Net margin-6.4%
FCF margin-1.7%
EBITDA margin3.4%
Returns
ROE-10.1%
ROA-5.0%
ROIC (approx.)-4.2%
Asset turnover0.79x
Leverage & solvency
Liabilities / assets43.6%
Debt / equity0.35x
Current ratio0.85x
Interest coverage-1.40x
Cash quality & payout
Operating cash flow / net income0.21x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $151.82M | $180.35M | $195.92M | $168.79M | $133.31M |
| Cost of revenue | $61.69M | $71.15M | $73.77M | $62.78M | $44.54M |
| Gross profit | $90.13M | $109.20M | $122.14M | $106.01M | $88.78M |
| SG&A expense | $82.18M | $98.88M | $102.38M | $101.42M | $65.73M |
| Operating income | -$11.56M | -$1.58M | $9.72M | -$4.54M | $15.77M |
| Interest expense | $6.08M | $6.25M | $6.49M | $6.75M | $4.89M |
| Pretax income | -$17.64M | -$7.83M | $3.24M | -$11.30M | $10.88M |
| Income tax | -$5.97M | $188,000 | $7.48M | $3.38M | $329,000 |
| Net income | -$11.67M | -$8.02M | -$4.24M | -$14.68M | $10.55M |
| EBITDA | $1.22M | $10.30M | $19.98M | $3.52M | $22.36M |
| EPS (basic) | -0.19 | -0.14 | -0.08 | -0.26 | -0.01 |
| EPS (diluted) | -0.19 | -0.14 | -0.08 | -0.26 | -0.01 |
| Dividends declared per share | — | — | — | 0.41 | — |
| Weighted avg. shares (diluted) | 60.45M | 57.69M | 56.78M | 55.68M | 55.64M |
| Balance sheet | |||||
| Cash & equivalents | $8.45M | $8.23M | $10.26M | $9.62M | $25.35M |
| Current assets | $15.46M | $17.12M | $15.96M | $16.68M | $29.44M |
| PP&E, net | $27.81M | $37.47M | $28.91M | $24.21M | $13.63M |
| Goodwill | $81.73M | $81.73M | $81.73M | $81.73M | $81.73M |
| Intangibles | $36.84M | $41.59M | $46.35M | $51.10M | $55.85M |
| Total assets | $187.30M | $212.78M | $204.02M | $200.76M | $200.55M |
| Current liabilities | $27.90M | $28.95M | $20.32M | $22.32M | $16.41M |
| Short-term debt | $5.46M | $4.25M | $2.12M | $2.12M | $850,000 |
| Long-term debt | $50.59M | $65.46M | $69.50M | $81.42M | $81.75M |
| Total debt | $56.05M | $69.71M | $71.63M | $83.55M | $82.61M |
| Total liabilities | $99.59M | $134.59M | $120.03M | $129.99M | $117.03M |
| Shareholders' equity | $87.71M | $78.19M | $82.66M | $70.77M | $83.53M |
| Net debt | $47.60M | $61.47M | $61.37M | $73.93M | $57.26M |
| Shares outstanding | 64.54M | 58.37M | 57.36M | 56.18M | 55.64M |
| Cash flow statement | |||||
| Operating cash flow | $3.10M | $11.35M | $23.96M | $24.45M | $26.63M |
| Capital expenditure | $2.40M | $14.01M | $9.92M | $12.92M | $7.12M |
| Free cash flow | $692,000 | -$2.66M | $14.04M | $11.53M | $19.52M |
| Investing cash flow | -$2.40M | -$14.01M | -$9.92M | -$12.92M | -$7.12M |
| Financing cash flow | -$478,000 | $630,000 | -$13.39M | -$27.26M | -$4.55M |
| Depreciation & amortization | $12.78M | $11.89M | $10.25M | $8.06M | $6.60M |
| Stock-based compensation | $2.33M | $3.76M | $18.22M | $29.46M | $7.18M |
| Dividends paid | $0 | $252,000 | $385,000 | $23.16M | $0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.